Topical Agents Currently in Phase II or Phase III Trials for Atopic Dermatitis.

Topical Agents Currently in Phase II or Phase III Trials for Atopic Dermatitis. J Drugs Dermatol. 2020 Oct 01;19(10):956-959 Authors: Uppal SK, Chat VS, Kearns DG, Wu JJ Abstract Mild to moderate atopic dermatitis (AD) occurs frequently in children and adults and is usually managed through the use of pharmacologic treatments, such as topical corticosteroids (TCS) and topical calcineurin inhibitors (TCIs), and good skin care practices. As chronic TCS or TCI can lead to the development of adverse effects, there is a need for safe, alternative treatments for patients with resistant AD. A systemic literature review was performed to examine the safety and efficacy of topical agents currently in phase II and phase III clinical trials for AD. Our team searched the databases, PubMed, Google Scholar, and ClinicalTrials.gov, on March 2020 for studies pertaining to the use of topical agents in AD. Key words included each drug (tapinarof, crisaborole, ARQ-151 cream, ruxolitinib) or “topical agents” combined with “atopic dermatitis.” Articles published within the last 5 years were included as references. References within retrieved articles were also reviewed to identify potentially missed studies. A total of 24 articles were included in this review. Tapinarof, crisaborole, and ruxolitinib lead to statistically significant improvements in multiple disease severity scores. ARQ-151 cream achieved statistical significance in secondary endpoints, i...
Source: Journal of Drugs in Dermatology - Category: Dermatology Tags: J Drugs Dermatol Source Type: research

Related Links:

ABSTRACTAtopic dermatitis (AD) is an incurable, inflammatory skin condition that is prevalent ( ∼20%) in young children. There is an unmet clinical need, particularly in children, for safe interventions that target the etiology of the disease. Deficiencies in the skin barrier protein, filaggrin (FLG) have been identified as major predisposing factors in AD. In mammals,l-histidine is rapidly incorporated into epidermal FLG and subsequent FLG proteolysis releasesl-histidine as an important natural moisturizing factor (NMF). It has therefore been hypothesized thatl-histidine supplementation would be a safe approach to aug...
Source: Journal of Nutrition - Category: Nutrition Source Type: research
Capsule summary Despite the absence of robust evidence, tacrolimus is quite commonly used off label as maintenance treatment for seborrheic dermatitis, in clinical practice. Tacrolimus 0.1% ointment applied twice a week after 7 days of topical corticosteroids is more effective than ciclopiroxolamine 1% as maintenance therapy in patients with severe facial seborrheic dermatitis.
Source: Journal of the American Academy of Dermatology - Category: Dermatology Authors: Source Type: research
Abstract BACKGROUND: Tralokinumab is a fully human monoclonal antibody that specifically neutralizes interleukin-13, a key driver of atopic dermatitis (AD). OBJECTIVES: To evaluate the efficacy and safety of tralokinumab in combination with TCS in patients with moderate-to-severe AD who were candidates for systemic therapy. METHODS: This was a double-blind, placebo plus optional TCS-controlled phase III trial. Patients were randomized 2 : 1 to subcutaneous tralokinumab 300 mg or placebo every 2 weeks (Q2W) with TCS as needed over 16 weeks. Patients who achieved an Investigator's Global Assessment (I...
Source: The British Journal of Dermatology - Category: Dermatology Authors: Tags: Br J Dermatol Source Type: research
Tralokinumab for moderate-to-severe atopic dermatitis: results from two 52-week, randomized, double-blind, multicentre, placebo-controlled phase III trials (ECZTRA 1 and ECZTRA 2). Br J Dermatol. 2020 Sep 30;: Authors: Wollenberg A, Blauvelt A, Guttman-Yassky E, Worm M, Lynde C, Lacour JP, Spelman L, Katoh N, Saeki H, Poulin Y, Lesiak A, Kircik L, Cho SH, Herranz P, Cork MJ, Peris K, Steffensen LA, Bang B, Kuznetsova A, Jensen TN, Østerdal ML, Simpson EL Abstract BACKGROUND: Tralokinumab, a fully human monoclonal antibody, specifically neutralizes interleukin-13, a key cytokine driving per...
Source: The British Journal of Dermatology - Category: Dermatology Authors: Tags: Br J Dermatol Source Type: research
This study will also provide supportive evidence to that provided by currently ongoing studies on the efficacy and safety of sarilumab in this clinical context.Trial designA phase two multi-center randomised controlled trial (RCT) with two parallel arms (1:1 ratio).ParticipantsThey will be hospitalized patients, of at least 18 years of age, with severe COVID-19 who have positive RT-PCR test and have radiographic evidence of pulmonary infiltrates by imaging or rales/crackles on exam and SpO2 ≤ 94% on room air that requires supplemental oxygen. Patients must present elevation of inflammatory parameters (IL-6> 40 pg/mL ...
Source: Trials - Category: Research Source Type: clinical trials
Publication date: Available online 2 September 2020Source: The Journal of Allergy and Clinical Immunology: In PracticeAuthor(s): Caroline Meyer Olesen, Ana B. Pavel, Jianni Wu, Daniela Mikhaylov, Ester Del Duca, Yeriel Estrada, James G. Krueger, Ning Zhang, Maja-Lisa Clausen, Tove Agner, Emma Guttman-Yassky
Source: The Journal of Allergy and Clinical Immunology: In Practice - Category: Allergy & Immunology Source Type: research
Eosinophilic otitis media (EOM) is an intractable otitis media mostly associated with bronchial asthma. Dupilumab, an anti-interleukin (IL)-4 receptor (R) α, is effective and has been approved for use in patients with moderate to severe bronchial asthma, atopic dermatitis and chronic rhinosinusitis with nasal polyposis, whose diseases are not controlled by previous treatments including other molecular targeted drugs. We aimed to assess efficacy of du pilumab in three EOM patients with associated bronchial asthma, who were poor responders to previous topical and systemic corticosteroid therapy and molecular targeted therapies.
Source: Auris, Nasus, Larynx - Category: ENT & OMF Authors: Tags: Original Article Source Type: research
Discussion: The systematic review mainly to access the safety and efficacy of tacrolimus ointment for hormone-dependent dermatitis (facial corticosteroid addiction dermatitis and facial steroid dermatitis). The results of our research will facilitate evidence-based management of patients with facial corticosteroid-dependent dermatitis and provide clinical advice on their treatment options. Registration: PROSPERO CRD42020171813.
Source: Medicine - Category: Internal Medicine Tags: Research Article: Study Protocol Systematic Review Source Type: research
Baricitinib may provide another treatment option for patients with atopic dermatitis who did not adequately respond to corticosteroid therapy.The British Journal of Dermatology
Source: Medscape Allergy Headlines - Category: Allergy & Immunology Tags: Dermatology Journal Article Source Type: news
Publication date: Available online 2 September 2020Source: The Journal of Allergy and Clinical Immunology: In PracticeAuthor(s): Caroline Meyer Olesen, Ana B. Pavel, Jianni Wu, Daniela Mikhaylov, Ester Del Duca, Yeriel Estrada, James G. Krueger, Ning Zhang, Maja-Lisa Clausen, Tove Agner, Emma Guttman-Yassky
Source: The Journal of Allergy and Clinical Immunology: In Practice - Category: Allergy & Immunology Source Type: research
More News: Child Development | Children | Clinical Trials | Corticosteroid Therapy | Databases & Libraries | Dermatitis | Dermatology | Skin | Statistics | Study